Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology

Incidence of Treatment-resistant depression

6 evidence topics · 6 sources

United States commercial, Medicaid, and Medicare claims: incidence by operating definition
DatabaseCap on time for a regimen to failNumber of casesIncidence estimateIncidence 95% CI
CCAE3 months“4,791”View highlighted excerpt for this quote“33.93”View highlighted excerpt for this quote“32.97, 34.89”View highlighted excerpt for this quote
MDCD3 months“661”View highlighted excerpt for this quote“65.71”View highlighted excerpt for this quote“60.71, 70.72”View highlighted excerpt for this quote
MDCR3 months“228”View highlighted excerpt for this quote“13.08”View highlighted excerpt for this quote“11.39, 14.78”View highlighted excerpt for this quote
CCAE6 months“7,130”View highlighted excerpt for this quote“50.49”View highlighted excerpt for this quote“49.33, 51.65”View highlighted excerpt for this quote
MDCD6 months“987”View highlighted excerpt for this quote“98.12”View highlighted excerpt for this quote“92.01, 104.24”View highlighted excerpt for this quote
MDCR6 months“320”View highlighted excerpt for this quote“18.36”View highlighted excerpt for this quote“16.36, 20.37”View highlighted excerpt for this quote
CCAE24 months“9,038”View highlighted excerpt for this quote“64.00”View highlighted excerpt for this quote“62.69, 65.32”View highlighted excerpt for this quote
MDCD24 months“1,209”View highlighted excerpt for this quote“120.20”View highlighted excerpt for this quote“113.43, 126.96”View highlighted excerpt for this quote
MDCR24 months“404”View highlighted excerpt for this quote“23.19”View highlighted excerpt for this quote“20.93, 25.45”View highlighted excerpt for this quote

“Incidence/100,000 cohort members/year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Truven MarketScan Commercial Claims and Encounters (CCAE), with approximately 35 million mainly privately insured subscribers in 2011; Truven MarketScan Medicaid (MDCD), a means-tested public insurance program with approximately 5 million subscribers in 2011, and Truven MarketScan Medicare Supplemental Beneficiaries (MCDR), a public insurance program that is not means-tested, with approximately 3 million subscribers in 2011, most of whom were aged 65 or older.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“we defined TRD as failure of two medications as evidenced by their replacement or supplementation by other medications, and set maximum durations (caps) for how long a medication regimen could remain in use and still be eligible to fail.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“TRD incidence estimates varied approximately 2-fold between the two databases (CCAE, Medicaid) that described socioeconomically different non-elderly populations; for a given cap varied 2-fold to 4-fold within each database across the other implementation choices; and if the cap was also allowed to vary, varied 6-fold or 7-fold within each database.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“among such studies the proportion of PTD cases that develop into TRD cases ranges from 35% in a study limited to PTD subjects with a diagnosis of MDD [9] to less than 10% in a study that included a wider range of depression diagnoses among the PTD subjects” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote